Search results for " METASTASES"

showing 10 items of 100 documents

Reconstruction of vertebral body after radiofrequency ablation and augmentation in dorsolumbar metastatic vertebral fracture: Analysis of clinical an…

2017

Background: Painful spinal metastases usually occur in malignant neoplastic disease. Treatment for bone metastases has been largely conservative, and it includes the use of high doses of analgesics, radiotherapy, chemotherapy, hormone therapy, and bisphosphonates; however, results are sometimes transient and ineffective. In the presence of neurological involvement a surgical strategy should be considered. Recently, percutaneous procedures such as radiofrequency ablation, vertebroplasty, and kyphoplasty have been introduced as palliative techniques to treat painful vertebral metastases [3, 11, 25]. Methods: In our study we combined the use of radiofrequency ablation with vertebroplasty in th…

medicine.medical_specialtyPercutaneousRadiofrequency ablationmedicine.medical_treatment030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicinelawmedicineMinimally invasive spinal surgeryChemotherapyVertebroplasty.business.industrySettore MED/27 - NeurochirurgiaRadiofrequency ablationSurgeryVertebral bodyRadiation therapy030220 oncology & carcinogenesisRadiological weaponSpinal metastaseRadiologyHormone therapyVertebral fracturebusinessSpinal metastases
researchProduct

Value of serial magnetic resonance imaging in the assessment of brain metastases volume control during stereotactic radiosurgery

2016

AIM To evaluate brain metastases volume control capabilities of stereotactic radiosurgery (SRS) through serial magnetic resonance (MR) imaging follow-up. METHODS MR examinations of 54 brain metastases in 31 patients before and after SRS were reviewed. Patients were included in this study if they had a pre-treatment MR examination and serial follow-up MR examinations at 6 wk, 9 wk, 12 wk, and 12 mo after SRS. The metastasis volume change was categorized at each follow-up as increased (> 20% of the initial volume), stable (± 20% of the initial volume) or decreased (< 20% of the initial volume). RESULTS A local tumor control with a significant (P < 0.05) volume decrease was observed in 25 meta…

medicine.medical_specialtyPseudo progressionBrain metastasemedicine.medical_treatmentPseudo-progressionVolume controlRadiosurgery03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineRetrospective StudymedicineStereotactic radiosurgerymedicine.diagnostic_testbusiness.industryBrain metastasesMagnetic resonance imagingequipment and suppliesRadiation therapyRadiation therapySerial magnetic resonance imaging030220 oncology & carcinogenesisRadiologyNuclear medicinebusinesshuman activities030217 neurology & neurosurgeryWorld Journal of Radiology
researchProduct

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-ana…

2020

Background The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with denosumab or zoledronic acid (ZA). Material and Methods An electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and …

medicine.medical_specialtymedication-related osteonecrosis of the jawsPHASE-3SKELETAL-RELATED EVENTSneoplasmsbisphosphonate-associated osteonecrosis of the JawsReviewBREASTZoledronic AcidDISEASElaw.invention03 medical and health scienceszoledronic acidDOUBLE-BLIND0302 clinical medicineRandomized controlled triallawInternal medicineNeoplasmsDentistry Oral Surgery & MedicinemedicineHumansGeneral DentistryRISKBONE METASTASESBisphosphonate-associated osteonecrosis of the jawScience & TechnologyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)030206 dentistryOdds ratiomedicine.disease:CIENCIAS MÉDICAS [UNESCO]DenosumabZoledronic acidOtorhinolaryngologyMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessLife Sciences & Biomedicinemedicine.drug
researchProduct

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.

2015

The immunostimulatory ability of synthetic oligonucleotides containing CpG motifs (CpG-ODN), agonists of Toll-like receptor 9 (TLR9), can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate local activation of innate immunity; however, particularly in the lung, tumor-associated immunosuppression can subvert such antitumor innate immune responses. To locally maintain continuous activation of innate subpopulations while inhibiting immunosuppressive cells, we evaluated aerosol delivery CpG-ODN combined with Poly(I:C), a TLR3 agonist able to convert tumor-supporting macrophages to tumoricidal effectors, in the treatment of B16 melanoma lung metastases …

miceCpG Oligodeoxynucleotidemedicine.medical_treatmentDacarbazineImmunologySettore MED/08 - Anatomia Patologicaaerosol delivery; dacarbazin; lung metastases; mice; TLR agonists; Immunology and Allergy; Oncology; Immunologylung metastaseMedicineCytotoxic T cellImmunology and AllergyTLR agonistAerosolizationOriginal ResearchInnate immune systembusiness.industryTLR9Immunosuppressionhemic and immune systemsrespiratory systemOncologydacarbazinTLR3ImmunologyCancer researchaerosol deliverybusinessmedicine.drug
researchProduct

CONGENITAL NEUROBLASTOMA: A RARE CASE OF PLURIVISCERAL METASTATIC DISSEMINATION

2021

Neuroblastoma is one of the most common neonatal tumors. It involves children in early infancy and originates from neural crest cells of the adrenal gland medulla or sympathetic glia. We report an unusual case of congenital poorly differentiated neuroblastoma with multiple metastases in the brain and cerebellum. The biophysical profile showed a prominent polyhydramnios at 25.3 weeks of gestation; meantime, the mother was diagnosed with gestational diabetes. The mass was detected during the third ultrasonographic examination at 31.4 weeks of gestation. The fetus lived only one day after birth and the postmortem examinations were performed subsequently. An autopsy was performed both to unders…

neuroblastomaMedicine (General)R5-920neoplasm metastasescongenitalforensic autopsyEuromediterranean Biomedical Journal
researchProduct

Oral non-squamous malignant tumors: diagnosis and treatment

2007

Some 90% of oral cancers consist of squamous cell carcinomas that arise from the oral mucosa. The remaining 10% of malignancies consist of malignant melanomas, carcinomas of the intraoral salivary glands, sarcomas of the soft tissues and the bones, malignant odontogenic tumors, non-Hodgkin?s lymphomas and metastases from primary tumors located elsewhere in the body. These malignancies will be briefly reviewed and discussed. The emphasis is on diagnosis and management.

oral malignant melanomaoral metastasesOral cancerUNESCO::CIENCIAS MÉDICASoral sarcoma:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single …

2022

Background: Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction mainly associated to bone modifying agents (BMAs). Breast cancer (BC) is the most frequent cancer worldwide. Its therapy can cause cancer treatment-induced bone loss (CTIBL), commonly treated with BMAs. The aims of this retrospective study are: to describe characteristics of BC patients under BMAs for CTIBL; to record any switch to high-dose BMAs; to assess MRONJ onset and to identify any factors associated with it. Patients: Authors included patients referred for MRONJ prevention to the Unit of Oral Medicine (University Hospital of Palermo). Results: Fourteen female BC patients under low-dose BMAs f…

osteonecrosis of the jawbisphosphonatebreast cancerBPosteonecrosis of the jaw; MRONJ; cancer treatment-induced bone loss; CTIBL; breast cancer; osteoporosis; bone metastases; bisphosphonates; BPs; denosumabcancer treatment-induced bone loosteoporosidenosumabPharmacology (medical)MRONJCTIBLbone metastaseOral; Volume 2; Issue 4; Pages: 274-285
researchProduct

CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer

2022

Simple Summary The lung is the second most common site of metastases in colorectal cancer (CRC). The aim of our study was to evaluate the prognostic value of CD3+ and CD8+ T-cell density based immune cell score (ICS) and PD-1/PD-L1 expression in resected pulmonary metastases of microsatellite stable CRC. The T-cell infiltration was higher in the first pulmonary metastases compared to primary tumour. Pulmonary metastases with high ICS had improved survival compared to low ICS after adjusting for confounders. High tumour cell PD-L1 expression was associated with favourable prognosis. Our results might have clinical feasibility in planning future therapies. Abstract The objective of this study…

programmed death 1Cancer Research3122 Cancerscolorectal carcinoma; pulmonary metastases; tumour-infiltrating lymphocytes; programmed death 1; programmed death ligand 1karsinoomatetäpesäkkeetOncologycolorectal carcinomaprogrammed death ligand 11182 Biochemistry cell and molecular biologypulmonary metastasessyöpätaudittumour-infiltrating lymphocyteskeuhkotpaksusuolisyöpä
researchProduct

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

2020

Introduction: The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. Areas covered: This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper. Expert opinion: As shown in phase 2 and 3 clinical trials on …

safetyAminopyridinesBreast Neoplasms030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundabemaciclib breast cancer metastases hormonal receptors safetybreast cancer0302 clinical medicineBreast cancerCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)metastasesskin and connective tissue diseasesFulvestrantProtein Kinase InhibitorsAbemaciclibbiologyAromatase Inhibitorsbusiness.industryKinasehormonal receptorsCyclin-Dependent Kinase 4Cell Cycle CheckpointsCyclin-Dependent Kinase 6General Medicinemedicine.diseaseAbemaciclibchemistry030220 oncology & carcinogenesisQuality of LifeCancer researchbiology.proteinBenzimidazolesFemalesense organsbusinessHormone
researchProduct

Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis.

2007

Cathepsin K serum levels were determinated in patients with bone metastases from breast cancer or prostate cancer in therapy with zoledronic acid or in patients or in patients with located breast or prostate cancer end in patients with non malignant diseases and in healthy blood. donors (control group). Cathepsin K serum levels were significantly more eleved in healthy subjects or in patients with peimary osteoporosis. Furthermore, the administration of Zoledronic acid to patients with metastatic bome disease from breast or prostate cancer, induced a marked increase of Cathepsin K serum levels.

zoledronic acid cathepsin k bone metastases
researchProduct